Applications of Proteomics to Clinical Questions in Breast Cancer

Aprelikova, O., A. J. Pace, et al. (2001). BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. J Biol Chem 276(28): 25647–50.PubMedCrossRefGoogle Scholar

Banks, R. E., M. J. Dunn, et al. (2000). Proteomics: new perspectives, new biomedical opportunities. Lancet 356(9243): 1749–56.PubMedCrossRefGoogle Scholar

Bischoff, R., T. M. Luider (2004). Methodological advances in the discovery of protein and peptide disease markers. J Chromatogr B Analyt Technol Biomed Life Sci 803(1): 27–40.PubMedCrossRefGoogle Scholar

Blanckaert, V. D., M. Hebbar, et al. (1998). Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. Clin Cancer Res 4(12): 2939–47.PubMedGoogle Scholar

Chan, D. W., R. A. Beveridge, et al. (1997). Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 15(6): 2322–8.PubMedGoogle Scholar

Chaurand P, S. S., Caprioli R. M. (2004). Assessing protein patterns in disease using imaging mass spectrometry. J Proteome Res 3(2): 245–52.PubMedCrossRefGoogle Scholar

Chen, S. T., T. L. Pan, et al. (2002). Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett 181(1): 95–107.PubMedCrossRefGoogle Scholar

Clarke, W., Z. Zhang, et al. (2003). The application of clinical proteomics to cancer and other diseases. Clin Chem Lab Med 41(12): 1562–70.PubMedCrossRefGoogle Scholar

Cobleigh, M. A., C. L. Vogel, et al. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17(9): 2639–48.PubMedGoogle Scholar

Colomer, R., L. A. Shamon, et al. (2001). Herceptin: from the bench to the clinic. Cancer Invest 19(1): 49–56.PubMedCrossRefGoogle Scholar

Descamps, S., X. Lebourhis, et al. (1998). Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells. J Biol Chem 273(27): 16659–62.PubMedCrossRefGoogle Scholar

Elmore, J. G., M. B. Barton, et al. (1998). Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 338(16): 1089–96.PubMedCrossRefGoogle Scholar

Espina, V., A. I. Mehta, et al. (2003). Protein microarrays: molecular profiling technologies for clinical specimens. Proteomics 3(11): 2091–100.PubMedCrossRefGoogle Scholar

Esteva, F. J., G. N. Hortobagyi (2004). Prognostic molecular markers in early breast cancer. Breast Cancer Res 6(3): 109–18.PubMedCrossRefGoogle Scholar

Fu, H., R. R. Subramanian, et al. (2000). 14-3-3 proteins: structure, function, and regulation. Annu Rev Pharmacol Toxicol 40: 617–47.PubMedCrossRefGoogle Scholar

Hanash, S. (2004). The role of proteomic analyses in breast cancer. Pathogen Breast Cancer.Google Scholar

Hondermarck, H., L. Dolle, et al. (2002). Functional proteomics of breast cancer for signal pathway profiling and target discovery. J Mammary Gland Biol Neoplasia 7(4): 395–405.PubMedCrossRefGoogle Scholar

Hondermarck, H., A. S. Vercoutter-Edouart, et al. (2001). Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 1(10): 1216–32.PubMedCrossRefGoogle Scholar

Hu, H., H. Brzeski, et al. (2004). Biomedical informatics: development of a comprehensive data warehouse for clinical and genomic breast cancer research. Pharmacogenomics 5(7): 933–41.PubMedCrossRefGoogle Scholar

Jain, K. K. (2004). Applications of biochips: from diagnostics to personalized medicine. Curr Opin Drug Discov Devel 7(3): 285–9.PubMedGoogle Scholar

Jeffrey, S. S., J. R. Pollack (2003). The diagnosis and management of pre-invasive breast disease: promise of new technologies in understanding pre-invasive breast lesions. Breast Cancer Res 5(6): 320–8.PubMedCrossRefGoogle Scholar

Jemal, A., A. Thomas, et al. (2002). Cancer statistics, 2002. CA Cancer J Clin 52(1): 23–47.PubMedCrossRefGoogle Scholar

Laronga, C., H. Y. Yang, et al. (2000). Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J Biol Chem 275(30): 23106–12.PubMedCrossRefGoogle Scholar

Li, J., Z. Zhang, et al. (2002). Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48(8): 1296–304.PubMedGoogle Scholar

Liotta, L. A., M. Ferrari, et al. (2003). Clinical proteomics: written in blood. Nature 425(6961): 905.PubMedCrossRefGoogle Scholar

Liu, J. F., E. Chevet, et al. (1999). Functional Rac-1 and Nck signaling networks are required for FGF-2-induced DNA synthesis in MCF-7 cells. Oncogene 18(47): 6425–33.PubMedCrossRefGoogle Scholar

Majid AS, d. P. E., Doherty RD, Sharma NR, Salvador X. (2003). Missed breast carcinoma: pitfalls and pearls. Radiographics 23(4): 881–95.PubMedCrossRefGoogle Scholar

McCallum, M., C. Baker, et al. (2004). A prognostic index for operable, node-negative breast cancer. Br J Cancer 90(10): 1933–41.PubMedCrossRefGoogle Scholar

Nurcombe, V., C. E. Smart, et al. (2000). The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. J Biol Chem 275(39): 30009–18.PubMedCrossRefGoogle Scholar

Pandey, A., A. V. Podtelejnikov, et al. (2000). Analysis of receptor signaling pathways by mass spectrometry: identification of vav-2 as a substrate of the epidermal and platelet-derived growth factor receptors. Proc Natl Acad Sci U S A 97(1): 179–84.PubMedCrossRefGoogle Scholar

Paweletz, C. P., B. Trock, et al. (2001). Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 17(4): 301–7.PubMedGoogle Scholar

Peng, C. Y., P. R. Graves, et al. (1997). Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277(5331): 1501–5.PubMedCrossRefGoogle Scholar

Petricoin, E., V. E. Bischel, et al. (2005). Mapping Molecular Networks using Proteomics: a vision for patient-tailored combination therapy. J Clin Oncol 23(15): 3614–21.PubMedCrossRefGoogle Scholar

Petricoin, E. E., C. P. Paweletz, et al. (2002). Clinical applications of proteomics: proteomic pattern diagnostics. J Mammary Gland Biol Neoplasia 7(4): 433–40.PubMedCrossRefGoogle Scholar

Petricoin, E. F., A. M. Ardekani, et al. (2002). Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306): 572–7.PubMedCrossRefGoogle Scholar

Petricoin, E. F., L. A. Liotta (2004). SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 15(1): 24–30.PubMedCrossRefGoogle Scholar

Pusztai, L., B. W. Gregory, et al. (2004). Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinoma. Cancer 100(9): 1814–22.PubMedCrossRefGoogle Scholar

Rahmoune, H., H. L. Chen, et al. (1998). Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. J Biol Chem 273(13): 7303–10.PubMedCrossRefGoogle Scholar

Sauter, E. R., W. Zhu, et al. (2002). Proteomic analysis of nipple aspirate fluid to detect biologic markers of breast cancer. Br J Cancer 86(9): 1440–3.PubMedCrossRefGoogle Scholar

Sell, S. (1990). Cancer markers of the 1990s. Comparison of the new generation of markers defined by monoclonal antibodies and oncogene probes to prototypic markers. Clin Lab Med 10(1): 1–37.PubMedGoogle Scholar

Shin, B. K., H. Wang, et al. (2002). Proteomics approaches to uncover the repertoire of circulating biomarkers for breast cancer. J Mammary Gland Biol Neoplasia 7(4): 407–13.PubMedCrossRefGoogle Scholar

Slamon D. J., B. Leyland-Jones, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11): 783–92.PubMedCrossRefGoogle Scholar

Souchelnytskyi, S. (2002). Proteomics in studies of signal transduction in epithelial cells. J Mammary Gland Biol Neoplasia 7(4): 359–71.PubMedCrossRefGoogle Scholar

Varnum, S. M., C. C. Covington, et al. (2003). Proteomic characterization of nipple aspirate fluid: identification of potential biomarkers of breast cancer. Breast Cancer Res Treat 80(1): 87–97.PubMedCrossRefGoogle Scholar

Vercoutter-Edouart, A. S., X. Czeszak, et al. (2001). Proteomic detection of changes in protein synthesis induced by fibroblast growth factor-2 in MCF-7 human breast cancer cells. Exp Cell Res 262(1): 59–68.PubMedCrossRefGoogle Scholar

Vercoutter-Edouart, A. S., J. Lemoine, et al. (2001). Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res 61(1): 76–80.PubMedGoogle Scholar

Wright, G. L., Jr. (1974). Two-dimensional acrylamide gel electrophoresis of cancer-patient serum proteins. Ann Lab Sci 4: 281–293.Google Scholar

Wulfkuhle, J. D., J. A. Aquino, et al. (2003). Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3(11): 2085–90.PubMedCrossRefGoogle Scholar

Wulfkuhle, J. D., K. C. McLean, et al. (2001). New approaches to proteomic analysis of breast cancer. Proteomics 1(10): 1205–15.PubMedCrossRefGoogle Scholar

Wulfkuhle, J. D., D. C. Sgroi, et al. (2002). Proteomics of human breast ductal carcinoma in situ. Cancer Res 62(22): 6740–9.PubMedGoogle Scholar

Yazidi-Belkoura, I. E., E. Adriaenssens, et al. (2002). Proteomics of breast cancer: outcomes and prospects. Technol Cancer Res Treat 1(4): 287–96.PubMedGoogle Scholar